Prelude Therapeutics Incorporated Stock Analysis & AI Score
Prelude Therapeutics Incorporated (PRLD) has an ST Score of 54.1 (B-), driven by its Forecast (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $8.00 price target (+100.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Prelude Therapeutics Incorporated (PRLD) has an ST Score of 54.1 (B-), driven by its Forecast (A) and held back by its Financial Strength (D+). Analysts rate it Buy with a $8.00 price target (+100.5% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthD+
All factor grades
- ForecastA
- ValuationB
- GrowthB
- MomentumB-
- ProfitabilityC+
- Financial StrengthD+
- Piotroski4/9
Contact
PRLD stock: frequently asked questions
What is PRLD's ST Score?
Prelude Therapeutics Incorporated (PRLD) has an ST Score of 54.1 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PRLD a buy, hold, or sell?
Analysts rate PRLD a Buy, with a price target of $8.00 (+100.5% vs the current price). Our ST Score grades it B- (54.1/100). The ST Score is a data-driven signal, not a recommendation.
What are PRLD's factor grades?
Valuation B, Profitability C+, Financial Strength D+, Momentum B-, Growth B, Forecast A.
What is PRLD's valuation grade?
Prelude Therapeutics Incorporated (PRLD) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PRLD's growth grade?
Prelude Therapeutics Incorporated (PRLD) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PRLD's profitability grade?
Prelude Therapeutics Incorporated (PRLD) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PRLD's financial strength grade?
Prelude Therapeutics Incorporated (PRLD) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PRLD?
The average analyst price target for Prelude Therapeutics Incorporated (PRLD) is $8.00 from 8 analysts, which is +100.5% versus the recent price of $3.99.
What is PRLD's Piotroski score?
Prelude Therapeutics Incorporated (PRLD) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.